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Abstract
Prior candidate gene studies have shown tumor suppressor DNA methylation in breast milk related with history of breast
biopsy, an established risk factor for breast cancer. To further establish the utility of breast milk as a tissue-specific
biospecimen for investigations of breast carcinogenesis, we measured genome-wide DNA methylation in breast milk from
women with and without a diagnosis of breast cancer in two independent cohorts. DNA methylation was assessed using
Illumina HumanMethylation450k in 87 breast milk samples. Through an epigenome-wide association study we explored
CpG sites associated with a breast cancer diagnosis in the prospectively collected milk samples from the breast that would
develop cancer compared with women without a diagnosis of breast cancer using linear mixed effects models adjusted for
history of breast biopsy, age, RefFreeCellMix cell estimates, time of delivery, array chip and subject as random effect. We
identified 58 differentially methylated CpG sites associated with a subsequent breast cancer diagnosis (q-value <0.05).
Nearly all CpG sites associated with a breast cancer diagnosis were hypomethylated in cases compared with controls and
were enriched for CpG islands. In addition, inferred repeat element methylation was lower in breast milk DNA from cases
compared to controls, and cases exhibited increased estimated epigenetic mitotic tick rate as well as DNA methylation age
compared with controls. Breast milk has utility as a biospecimen for prospective assessment of disease risk, for
understanding the underlying molecular basis of breast cancer risk factors and improving primary and secondary
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Introduction
Breast cancer is the most common non-keratinocyte cancer in
women in the USA, with over 270 000 new cases each year (1).
Established risk factors for breast cancer include age, reproduc-
tive history and family history of disease and can be used to
estimate disease risk (2,3). Additionally, and beyond the rec-
ognized role of inherited BRCA mutation, individual germline
genetic variants and even polygenic risk scores from genome-
wide association studies have also contributed to breast cancer
risk assessment (4–6). Nonetheless, a large gap in the capacity
to predict breast cancer risk remains, and the molecular basis
of breast cancer risk and carcinogenesis has largely not been
studied using target-organ biospecimens from premenopausal
women.
Epigenome-wide association studies (EWAS), using surrogate
tissues such as peripheral blood DNA, have also had some suc-
cess testing the relation of DNA methylation with cancer risk
(7–9). However, unlike genetic variation and germline alterations
that confer cancer risk, cytosine modifications that contribute
to cancer risk as disease initiating and promoting events are
overwhelmingly tissue-specific. Defining and leveraging knowl-
edge of tissue-specific early DNA methylation alterations for
screening or risk models in normal, non-tumor human tissues
is challenging for most common tumor types. Yet, use of breast-
specific substrate to investigate breast cancer risk has shown
promise in early studies measuring cell composition, cytology
and candidate gene DNA methylation from nipple aspirate fluid,
though as a substrate, nipple aspirate fluid can be challenging
to obtain and typically yields very low volume (10–14). Recently,
the utility of altered DNA methylation in cancer screening and
risk assessment was established in colon cancer as part of the
Cologuard multi-target assay where a tissue-specific biospeci-
men (stool) is obtained and measured without using an invasive
procedure (15).
The majority of extensive DNA methylation alterations
observed in invasive breast cancer compared with normal breast
tissue are already present in pre-invasive disease (16–18). In
addition, age-related variation in normal breast tissue DNA
methylation has been shown to occur at CpG sites that are
more likely to be altered in breast tumors (16), suggesting that
early measures of DNA methylation in the pathologically normal
breast have value as a biomarker for future breast cancer risk
(16). Typically, mammary epithelial cells cannot be accessed
without invasive procedures (breast biopsy), lavage or other
relatively impractical methods. However, exfoliated mammary
epithelial cells (lactocytes, myoepithelial and progenitor/stem
cells) are abundant in mature breast milk (as high as 98% of cells)
(19,20), providing a tissue-specific substrate obtained without
invasive procedure. These cells are an excellent target for
biomarker development, and prior candidate gene studies have
shown that methylation-induced silencing of tumor suppressor
genes in breast milk is related with history of breast biopsy,
an established risk factor for breast cancer (21–23). Also as we
learn more about human milk as a potential research target,
we are now aware of potential sources of variability for these
biospecimens (24). Given that 85% of 40-year-old women in the
USA have given birth (25), breast milk is a viable non-invasive
source of mammary epithelial cells (26). We investigate the
relation of early epigenetic alterations with breast cancer risk
using cells obtained from breast milk of women who did not
develop breast cancer (hereafter named as ‘controls’) compared
with prospectively collected milk specimens from subjects who
were later diagnosed with breast cancer.
Table 1. Subject characteristics
Variable N (%) or mean [range]
Controls (n = 64) Breast cancer
(n = 23)
P
Age (years) 33.2 [23–44] 36.3 [29–45] 0.01
BMI 26.5 [18.2–43.6] 25.2 [18.4–38.7] 0.40
BMI category 0.20
Normal/underweight 28 (43.8) 8 (34.8)
Overweight/obesity 27 (42.2) 13 (56.5)
Missing 9 (14.1) 2 (8.7)
Breast biopsy <0.001
No 50 (78.1) 0 (0.0)
Yes 14 (21.9) 23 (100.0)
Time since delivery
(months)
2.2 [0–10] 10.8 [0.2–20] <0.001
Parity 2 [1–5] 2 [1–4] <0.001
Milk sample N/A
Ipsilateral N/A 16 (69.6)
Contralateral N/A 7 (30.4)
Milk collection N/A
Pre-diagnosis N/A 20 (87.0)
Post-diagnosis N/A 3 (13.0)
Results
Genome-scale DNA methylation was measured in breast milk
samples from 87 subjects using the Illumina HumanMethyla-
tion450 beadchip. Subject demographic and sample details are
provided in Table 1. A total of 64 (73%) samples were from cancer-
free subjects and 23 were from subjects who had a breast cancer
diagnosis of which 20 (87%) were collected prior to diagnosis.
Milk samples from subjects with any breast cancer diagnosis
were classified according to whether the cancer was in the
ipsilateral or contralateral breast. Overall, about 70% of samples
from subjects with subsequent breast cancer were collected
from the ipsilateral breast (n = 14) and 30% were from the con-
tralateral breast (n = 6). Unless stated otherwise, here we sum-
marize the comparison between cancer-free subjects and those
with subsequent breast cancer focusing on the ipsilateral breast
and exploring the potential effects in the contralateral breast.
Results of comparisons between cancer-free subjects with the
other three groups are deposited in zenodo (27).
We used a reference-free cell type estimation approach to
identify the number of putative cell types and the proportions
of each cell type in each breast milk sample. The reference-
free method identified five putative cell types in human milk.
In unadjusted models, we observed differences in cell type pro-
portions between breast milk samples from women who did not
develop breast cancer (controls) compared with those diagnosed
with a new breast cancer (ipsilateral or contralateral) for three
of the five putative cell types. The proportions of cell types 2
and 3 were higher in subjects with a prospective diagnosis of
breast cancer than controls (P = 5.2E-06 and 7.1E-04), and the
proportion of cell type 4 was lower in milk from subjects with
breast cancer compared to controls (P = 1.2E-05) (Fig. 1). In these
models, differential abundance of putative cell types in controls
versus cases was similar irrespective of whether the samples
were from the ipsilateral or contralateral breast, or whether
the breast cancer diagnosis occurred prior or subsequent to
breast milk sample collection (see Additional File, Supplemen-
tary Material, Fig. S1). After adjusting for maternal age (years),
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type proportions were no longer associated with breast cancer
diagnosis. We also explored the cell composition of the samples
using a modified reference-based hierarchical EpiDISH approach
(28,29). The predominant cells were epithelial cells and ‘neu-
trophils’ (granulocytes and other related cells) (Additional File,
Supplementary Material, Fig. S2).
DNA methylation was compared using linear mixed effect
models adjusted for time since delivery in months, maternal
age in years, estimated cell type proportions and array chip
with subject as a random effect. We explored potential sources
of variability between the ipsilateral new breast cancer and
our model covariates, the major sources of variation were
time since delivery (r = 0.73) and age at donation (r = 0.22) and
putative cell types 2–4 (see Additional File, Supplementary
Material, Table S1). We identified 58 significantly differentially
methylated CpG sites associated with milk from the ipsilateral
breast after correction for multiple comparisons (q-value
<0.05). Among these 58 CpGs, two CpGs in island regions and
associated one with both the LRRC61 and ACTR3C genes and
the other with SLC18B1 (previously C6orf192) were significantly
hypermethylated in breast milk from subjects who were later
diagnosed with breast cancer (Fig. 2). The remaining 56 CpG sites
were significantly hypomethylated in prospectively collected
breast milk from the ipsilateral breast of subjects who developed
cancer compared with controls (Fig. 2). The most statistically
significantly hypomethylated CpG site related to breast cancer
diagnosis was located in the island region of the CLCC1 gene.
Additional genes with hypomethylated loci included TMSB10,
ZNF584, MAP10 (previously KIAA1383), TRIM27 and SEPTIN7
(previously SEPT7). A total of 32 of these CpGs also were
hypomethylated in prospectively collected milk from women
who developed cancer in the contralateral breast compared to
controls (Table 2). The full set of the unadjusted and adjusted
EWAS results are deposited in zenodo (27); an overview of the
results is available as Additional File, Supplementary Material,
Figure S3.
We accessed TCGA breast tumor data using cBioportal to
determine whether genes we identified as having hypomethy-
lated CpGs related to breast cancer were associated with
gene regulation. We found negative correlations between DNA
methylation with mRNA expression z-scores (RNA seq) for
many of these genes including ZNF584 (P = 2.41E-17), MAP10
(P = 1.61E-76), TRIM27 (P = 6.01E-14), LIMD2 (P = 1.14E-59) and
LDHA (P = 6.06E-06). In contrast, there was little to no correlation
between DNA methylation and expression of CLCC1 (Spearman
ρ = −0.03, P = 0.5), TMSB10 (ρ = −0.08, P = 0.07) and SEPTIN7
(ρ = −0.05, P = 0.2), see Additional File, Supplementary Material,
Figure S4. The range of DNA methylation level observed for each
CpG tested in the TCGA tumors was comparable to that observed
in our samples. When we compared the DNA methylation
level change between normal adjacent and breast cancer in
TCGA, 22 CpGs from our results followed the same direction in
TCGA samples including TRIM27 and MAP10 (see Additional File,
Supplementary Material, Table S2). Of those, seven CpGs were
also hypomethylated when comparing normal breast tissue
versus breast cancer tissue in the dataset by Teschendorff et al.
(18).
Given the preponderance of CpG-specific breast milk DNA
hypomethylation associated with breast cancer, and that repeat
element hypomethylation is well established in cancer, we
further assessed repetitive element methylation. To do so,
we inferred Alu (37 subfamilies) and LINE-1 (115 subfamilies)
DNA methylation using array data and the repetitive element
methylation prediction (REMP), as detailed in the Methods
section. None of the individual repetitive elements reached
statistical significance after multiple comparison correction.
The nominally significant are summarized in Additional
File, Supplementary Material, Table S3. Mean Alu subfamily
methylation was significantly lower in breast cancer cases
compared to controls (β = −0.21, P-value = 2.9E-4), and mean
LINE-1 subfamily methylation was also lower in cases than
controls (β = −0.073, P-value = 0.10) (Fig. 3).
To evaluate the location in the genome where breast
cancer-related DNA methylation alterations in breast milk were
occurring, we performed enrichment analyses for both genomic
context and gene sets. Differentially methylated CpGs (q-value
<0.05) associated with a subsequent diagnosis of breast cancer
were enriched for CpG island regions in milk from both the
ipsilateral and contralateral breast (Table 3). Among CpGs whose
methylation was significantly related with cancer diagnosis we
also tested for enrichment of gene sets using the molecular
signatures database (MSigDB) v. 6.2, and identified seven gene
sets enriched for the 32 CpG sites that were differentially
methylated in both ipsilateral and contralateral samples. The
top two pathways are related to highly conserved motif clusters
matching transcription factor binding sites (30). Three pathways
are related to upregulation of genes in CD8(+) T lymphocytes,
T regulatory cells and dendritic cells. Finally, two gene sets are
associated to tumor invasion (31) and granulocyte differentiation
in acute promyelocytic leukemia (32), see Additional File,
Supplementary Material, Table S4.
In univariate linear mixed effect analyses we also tested
for DNA methylation age acceleration and elevated epigenetic
mitotic clock tick rate (epiTOC) in association with breast cancer
status. The epiTOC estimates were significantly higher among
breast cancer subjects (β = 0.013, P-value = 3.2E-04, Fig. 4A); when
restricting to the ipsilateral samples the association was still sig-
nificant (β = 0.017, P-value = 5.4E-05). A marginal non-statistically
significant increase in age acceleration subjects with breast
cancer compared to controls was also observed in new cancer
diagnoses using samples from any breast (β = 2.7, P-value = 0.071,
Fig. 4B), and when restricting to the ipsilateral samples (β = 2.5,
P-value = 0.1).
Discussion
We identified significant differences in DNA methylation after
controlling for cell type and other confounders in subjects with
a subsequent diagnosis of breast cancer compared with controls.
In the subjects who were diagnosed with breast cancer after
the milk collection, nearly all of the significantly differentially
methylated CpGs were hypomethylated. Several of the genes
whose CpG sites were differentially methylated in prospectively
diagnosed cases have previously been associated with breast
cancer. For example, TMSB10 is overexpressed in breast cancer
cells, has elevated protein expression in serum of breast cancer
patients and is elevated with increasing breast cancer stage
and distant metastasis (33). Linking a systemic marker of breast
cancer risk to our tissue-specific approach, promoter CpG island
hypomethylation of ZNF584 was associated with a breast cancer
diagnosis both here and in peripheral blood DNA from breast
cancer patients (34). Further, using TCGA breast tumor data, we
showed the functional relationship of ZNF584 DNA methylation
with gene expression. We also observed hypomethylation at
CpGs in SEPTIN7, TRIM27, LIMD2 and LDHA, which have been
associated with breast cancer metastasis, invasion and prolifer-
ation, (35–38). Apart from SEPTIN7, all these genes showed nega-
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Figure 1. Percentage of reference-free cell estimates in subjects with and without breast cancer. Note: here all the samples from both contralateral (n = 6) and ipsilateral
breast (n = 20) are shown in the graph.
in TCGA breast cancer samples, again demonstrating functional
consequences of altered DNA methylation to gene regulation.
These results support our hypothesis that epigenetic alterations
in human milk have utility for non-invasive molecular assess-
ment of breast cancer risk.
Among subjects with incident breast cancer, the group of
hypomethylated CpGs found to be significantly differentially
methylated in milk samples from both contralateral and ipsi-
lateral breast compared to those from controls was enriched for
CpG island regions. Methylation at CpG island regions can reduce
gene expression in associated genes (39). Since the majority of
differentially methylated CpGs were hypomethylated, this may
correspond to increased expression of genes with promoters
in these regions, and consistent with our observations of
local and potentially systemic effects, our pathway enrich-
ment analyses identified both proto-oncogene signatures and
immune dysregulation signatures. One pathway with strong
enrichment is associated with a motif for the ELK-1 a regulator
of the c-Fos proto-oncogene which has been linked to growth
suppression in breast cancer cells (40). The second pathway
includes CpGs related to a motif for SP-1, a part of the Kruppel-
like family that also has been associated as a prognostic factor
in breast cancer (41). Three more pathways pointed to genes
upregulated in CD8(+) T lymphocytes, activated T-regulatory
cells and dendritic cells, cornerstones of tumor immune
response in breast cancer murine models (42). The remaining
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Figure 2. Volcano plots differentially methylated sites in milk from the ipsilateral breast in prospectively diagnosed cancer patients. Note: In red those CpGs that
were differentially methylated (q-value <0.05), 56 hypomethylated and 2 hypermethylated. Gene names were added to those CpG sites that overlapped with CpGs
differentially methylated in the contralateral breast.
We also observed differences in measures of methylation age
including the epiTOC estimator and non-significant differences
using the Horvath’s methylation age between breast cancer sub-
jects and control subjects. Notably, in our study population,
the subjects with a cancer diagnosis were slightly older than
control subjects. There have been inconsistent trends of accel-
erated age in normal breast tissues when using the Horvath
methylation age approach (16). Accelerated biologic age inferred
using DNA methylation has recently been associated with breast
cancer risk in a very large prospective study using peripheral
blood (43). However, to date, unlike peripheral blood, there are
no DNA methylation clocks for inference of biologic age that
are calibrated specifically to biospecimens from the breast. In
the future, larger breast-tissue-specific studies are needed to
advance our understanding and opportunity to leverage biologic
age estimates for breast cancer risk assessment and primary
prevention.
This study has several strengths and limitations. Strengths
of our study include the use of prospectively collected spec-
imens, tissue-specific measures of DNA methylation and two
independent cohorts. Although some subjects potentially had
clinically occult disease when providing a milk specimen, others
were not diagnosed until years later. Based on a cohort study
of women exposed to breast radiation due to benign disease,
the latency between the initiating event and the development
of a clinical stage ranged between 10 and 30 years (44). In our
cohort, the women who later developed breast cancer could have
already had an asymptomatic tumor that could be detected in
the exfoliated cells in the breast milk. One limitation of this
study is sample size, though investigating genome-scale DNA
methylation measures in breast milk is novel. One potential
limitation is that we pooled controls from two different cohorts
processed in different technical batches. Although we controlled
for technical differences in our models and used a conservative
approach that adjusted for cell estimates which also captures
technical differences, we cannot completely exclude some resid-
ual technical noise between cohorts affecting our results. In
the future, we expect to gather additional information about
the cell composition of breast milk samples that will allow the
application of improved reference-based approaches (includ-
ing additional cell subtypes not available in our exploratory
approach). This will allow discerning between closely related
cell types which currently are collapsed into wider categories
(subtypes of epithelial cells and immature/progenitor myeloid
cells).
We identified early DNA methylation alterations in breast
milk associated with subsequent breast cancer occurrence.
These loci were either in genes expressed in breast cancers,
related to breast cancer progression or found in peripheral blood
samples of women with breast cancer. Importantly, because
we identified both overlapping results with work that used
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Table 2. CpG loci that are hypomethylated in breast cancer
CpG ID Gene Enhancer Genomic context Both breastsa
cg00954003 TMSB10 Island Yes
cg22063056 CLCC1 Island Yes
cg04637598 x Island Yes
cg19286631 TRIM27 Open sea Yes
cg14399369 VRK2 Island Yes
cg02191044 MAP10 x N-Shore Yes
cg26421123 COMMD5 Island Yes
cg18453621 LMX1B Island Yes
cg01221484 ZNF584 Island Yes
cg15698995 NAT14 Island Yes
cg12538369 SERTAD1 Island Yes
cg06363887 UTP3 Island Yes
cg19337593 DHPS Island Yes
cg21458073 SEPTIN7 Island Yes
cg01996304 ZNF668 Island Yes
cg02014690 DGCR6 Island Yes
cg24104616 ZNF311 Open sea Yes
cg03644271 LDHA Island Yes
cg09974136 RAB34 x Island Yes
cg14500569 PTCH1 Island Yes
cg05698228 ENC1 Island Yes
cg09422220 ELMOD2 Island Yes
cg24663984 UBE4A x Island Yes
cg02236651 LIMD2 Island Yes
cg08790491 PSMA3-AS1; ARID4A Island Yes
cg20923184 x Open sea Yes
cg20605045 SFXN4 x Island No
cg14610853 EEF1A2 S-Shelf Yes
cg24471039 RAB3GAP1 Open sea No
cg09827701 USP19 Island No
cg06952862 NHEJ1 S-Shore Yes
cg19570943 MAGOHB Island Yes
cg16400434 PPME1; C2CD3 Island No
cg01228243 GPAT4 Island No
cg12276298 SEM1; FAM149B1 Island Yes
cg26973266 TRAF4 Island No
cg00496455 TUBA4A Island No
cg18522266 SMARCA4 Island No
cg19584875 KCNK13 Island No
cg20287461 TMEM102 N-Shore No
cg06094142 x Open sea No
cg26292521 GATA3-AS1; GATA3 x Island No
cg09523472 RAD21 Island Yes
cg16914272 H2BC15; H2AC15 Island Yes
cg04422896 C12orf43 Island No
cg04193422 PON2 Island No
cg19483159 DYNLT1 S-Shore No
cg05677943 x Open sea No
cg14328761 Open sea No
cg10291648 TIRAP Island No
cg25977304 POU2F1 Island No
cg21077559 TMEM155; PP12613 Island No
cg03243700 WDR5 Island No
cg04799218 LPCAT3 Island No
cg07496106 GPT2 Island No
cg24717401 CCM2 Island No
aHypomethylation statistically significant on both ipsilateral and contralateral breast milk samples compared to non-cancer controls or not. For those marked as no,
the hypomethylation was significant for the ipsilateral sample only.
to breast milk, we expect that our tissue-specific approach
has high potential for follow-up work. We expect that future
investigations of DNA methylation changes present in cells
from breast milk from disease-free women will have value
for risk assessment and primary prevention of breast cancer,
perhaps with specific strength in application to premenopausal
disease. However, larger studies are needed to validate our
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Figure 3. Differences in repetitive element CpG methylation by breast cancer status. Note: here all the samples from both contralateral (n = 6) and ipsilateral breast
(n = 20) are shown in the graph.
Table 3. Enrichment for genomic context in CpGs with q < 0.05
Breast cancer groupa Island regions Enhancer regions
OR (95% CI) Pb OR (95% CI) Pb
Ipsilateral 3.48 (1.75, 7.45) 9.3E-05 1.05 (0.45, 2.18) 8.5E-01
Contralateral 4.28 (1.64, 13.30) 8.6E-04 1.01 (0.30, 2.67) 1.0E+00
aReference level is controls with no breast cancer history.
bP determined using the Cochran–Mantel–Haenszel test.
a biospecimen for understanding the molecular basis of disease
risk and prospective risk assessment.
In conclusion, we assessed genome-wide DNA methylation
in breast milk from subjects with and without breast cancer;
specific loci were hypomethylated in breast cancer subjects
compared to control subjects. These differentially methylated
regions were more likely to occur in island regions of the
genome. Our results suggest that breast milk has utility for
prospective assessment of breast cancer risk.
Materials and Methods
Study population
Two different study populations were included in this study: (1)
women from the ‘Molecular Biomarkers for Assessing Breast-
Cancer Risk’ project at the University of Massachusetts Amherst
(UMass) and (2) participants of the New Hampshire Birth Cohort
Study (NHBCS) at Dartmouth College. UMass subjects were
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Figure 4. Measures of age inferred from methylation values. (A) Epigenetic mitotic clock tick rate (epiTOC) between controls and subjects who later developed breast
cancer. (B) Age acceleration (difference between chronological and DNA methylation age) between controls and subjects who later developed breast cancer. Note: Here
all the samples from both contralateral (n = 6) and ipsilateral breast (n = 20) are shown in the graph.
have recently given birth, and they had a history of either
breast biopsy or breast cancer. UMass subjects were asked
to provide one or two breast milk samples expressed in a
single pumping session. NHBCS participant characteristics have
been described previously (45). Briefly, NHBCS eligibility criteria
included: English speaking, literate and mentally competent
women carrying a singleton pregnancy, 18–45 years of age and
whose primary source of residential water was a private well.
Women who planned to move during pregnancy were excluded
from this study. NHBCS participants were asked to bring bilateral
breast milk samples to the postpartum follow-up appointment.
All study participants provided written informed consent prior
to the study according to the guidelines of Institutional Review
Board of the University of Massachusetts Amherst and the
Committee for the Protection of Human Subjects at Dartmouth.
Women in both studies were asked to complete a questionnaire
about general health, reproductive health and personal breast
biopsy and breast cancer history. Each woman’s samples were
classified into five different groups: (1) no breast cancer history,
(2) healthy breast, contralateral breast cancer before donation,
(3) ipsilateral breast cancer diagnosis before donation, (4) healthy
breast contralateral cancer diagnosis after donation and (5)
sample from the ipsilateral breast with cancer after donation. For
this analysis, we report the results of model milk samples from
control subjects and from subjects with a subsequent diagnosis
of breast cancer.
Sample collection
Using a previously described method (26), breast milk was pro-
cessed within 24 h of sample collection to obtain DNA. Briefly,
DNA was extracted from 1 to 10 ml of milk from each breast and
stored at −20◦C until DNA extraction.
DNA extraction and genome-wide DNA methylation
array
DNA was isolated using the Qiagen DNeasy Blood and Tis-
sue Kit (Qiagen, Valencia, CA) and bisulfite converted using
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randomized across several plates and subsequently subjected
to epigenome-wide DNA methylation assessment using Illu-
mina Infinium HumanMethylation450 BeadChip, which mea-
sured ∼485 000 CpG sites genome-wide (Illumina, San Diego, CA).
Microarrays were processed at USC core facility following stan-
dard protocols. The data were assembled using GenomeStudio
methylation software (Illumina) without normalization as per
the manufacturer’s instructions. The methylation status for each
individual CpG locus (β-value) was calculated as the ratio of fluo-
rescent signals (β = Max(M,0)/[Max(M,0) + Max(U,0) + 100]), rang-
ing from 0 (no methylation) to 1 (complete methylation) using
the average probe intensity for the methylated (M) and unmethy-
lated (U) alleles. We read the idat files using the minfi R pack-
age (46). β-values were background corrected using methylumi-
noob and normalized using functional normalization.(47) Our
pipeline included array control probes to assess sample quality
and evaluate potential problems such as poor bisulfite conver-
sion or color-specific issues for each array as described pre-
viously (48,49). All CpG loci on X and Y chromosomes, CpH
and loci with potential problems of cross-reactivity, tracking to
polymorphisms with minor allele frequencies over 5% for the
general population, or common copy number alterations,(50)
were excluded from the analysis, leaving 368 171 autosomal CpG
loci in 92 samples. Principal components analysis and multi-
ple dimension scaling were used to identify potential technical
batches. Additionally, we used a principal component regression
analysis to investigate the top eight principal components in
relation to potential batch-associated differences. Subjects with
missing covariate data were excluded from modeling, resulting
in 87 samples. DNA methylation β-values were logit2 trans-
formed to M-values for the analyses (51).
Cell mixture analysis
Given the lack of cell-specific DNA methylation references for
most of the breast epithelial cell subtypes being interrogated
(lactocytes, myoepithelial, progenitor cells, among others) (20),
we were unable to apply a reference-based approach to cell
type deconvolution in the EWAS models. Instead, to identify
and adjust for potential cell type heterogeneity in the breast
milk samples, we used a reference-free decomposition (RefFree-
CellMix) of the DNA methylation matrix into cell-type distribu-
tions and cell-type methylomes, using the expression Y = M∗ΩT
(52). We explored a range of k cell types from 2 to 10. Note
that the decomposition will be based on Y, but Yfinal (=Y by
default) was used to determine the final value of M based on
the last iterated value of Ω. We explored the global cell com-
position of the samples using a modified hierarchical EpiDISH
approach. As references we used the epithelial, fibroblast and
immune cell matrix included in EpiDISH and for the immune
cell composition we used the legacy 450 k library included in
FlowSorted.Blood.EPIC (28,29), cell proportions were estimated
through robust partial correlations.
Locus-by-locus analysis for detecting differentially
methylated CpG loci
We implemented a locus-by-locus analysis to identify differ-
entially methylated CpG sites between samples obtained from
control subjects without breast cancer diagnosis and those from
healthy and diseased breasts before or after the cancer develop-
ment using the R package limma (53). Five groups were compared:
(1) Controls with no breast cancer history, (2) Contralateral Prior
Diagnosis (sample from healthy breast of a woman previously
diagnosed breast cancer), (3) Ipsilateral Prior Diagnosis (sample
from affected breast of a woman previously diagnosed breast
cancer), (4) Contralateral New Diagnosis (sample from healthy
breast of a woman with incident breast cancer) and (5) Ipsilateral
New Diagnosis (sample from affected breast of a woman with
incident breast cancer). Briefly, linear mixed effects models were
fit to each CpG site separately, with the CpG β-value as the
response against the five groups. A random effect for subject was
included to control for within subject correlation in subjects with
bilateral samples (30 subjects). The models were adjusted for
time from delivery (in months), maternal age (in years), RefFree-
CellMix proportion estimates (five putative cell types), and the
microarray slide to control residual batch confounding. P-values
were adjusted for multiple comparisons by computing the Ben-
jamini–Hochberg q-values (54), and we defined loci with q-value
< 0.05 to be statistically significant. For this analysis, we focus
on CpGs identified as differentially methylated in both prospec-
tively diagnosed groups (ipsilateral and contralateral) and report
individual group results in supplemental material (27). All analy-
ses were carried out using the R statistical package, version 3.5.0
(Vienna, Austria; www.r-project.org/) (55). We accessed TCGA
breast tumor data using cBioportal to determine whether genes
we identified as having hypomethylated CpGs related to breast
cancer were also associated with gene regulation. Finally, we
used public data from TCGA (774 breast cancer samples and 97
normal adjacent breast tissue) and from Teschendorff et al. (305
breast cancer samples and 50 normal breast tissue, deposited
in GEO, GSE69914) (18) to explore whether the CpGs observed
in our analyses were following the same directionality when
comparing normal breast tissue (or normal-adjacent tissue for
TCGA) versus breast cancer tissue.
Repetitive element prediction and analysis
We use the package REMP (56) to estimate the DNA methylation
levels on both LINE-1 and Alu transposons using the informa-
tion from the DNA methylation microarray. This random forest
approach covers 37 Alu subfamilies and 115 LINE-1 subfamilies.
We computed the average Alu and LINE-1 methylation levels for
each sample, and tested the association with prospectively diag-
nosed breast cancer, excluding the three samples from subjects
with a prior diagnosis of breast cancer. P-values were computed
using the Kenward–Roger approach.
Enrichment analyses
The probes that were differentially methylated were tested for
pathway and gene set enrichment using missMethyl (57) and the
MSigDB v.6.2 curated database (58). A minimum of two genes
were required for further exploring the specific pathway. We
also tested for over- or underrepresentation of differentially
methylated CpGs identified in the locus-by-locus analysis in (1)
enhancer regions and (2) CpG island regions. Loci with a q-value
<0.05 were considered to be statistically significant. Odds ratios,
95% confidence intervals and P-values were computed with the
Cochran–Mantel–Haenszel test and were adjusted for probe type.
Predicted methylation age and stem cell divisions
We used Horvath’s DNA methylation age estimation algorithm
(59) to calculate predicted methylation age (mAge) using the
agep function from wateRmelon (60). Using those estimates, age
acceleration was defined as: Age acceleration = mAge − Age.
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subjects and subjects with breast cancer using a linear mixed
effects model to control for within subject correlations. P-values
were calculated using the Kenward–Roger approach. Addition-
ally, stem cell divisions were estimated using the epiTOC method
(61), but only 334 of 385 CpGs were available to calculate esti-
mates. epiTOC estimates were compared between cases and
controls using unadjusted linear mixed effect models analo-
gously to the age acceleration models.
Supplementary Material
Supplementary material is available at HMG online.
Availability of data and material
The datasets generated and analyzed during the current study
are available in the GEO (https://www.ncbi.nlm.nih.gov/geo/)
under the accession number GSE133918. We also used the public
dataset by Teschendorff et al. available under the accession
number GSE69914, and the data from TCGA available through
https://gdac.broadinstitute.org/. The EWAS results (unadjusted
and adjusted for confounding covariates) are deposited in
Zenodo (https://doi.org/10.5281/zenodo.3362478).
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